{"brief_title": "A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients", "brief_summary": "This study will assess the efficacy and safety of intravenous (iv) or subcutaneous (sc) Mircera, administered with pre-filled syringes, as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv or sc epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.", "condition": ["Anemia"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["epoetin alfa or beta", "methoxy polyethylene glycol-epoetin beta [Mircera]"], "description": ["iv or sc, as prescribed", "30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks"], "arm_group_label": ["2", "1"], "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - chronic renal anemia; - on dialysis therapy for at least 12 weeks before screening; - receiving iv or sc epoetin for at least 8 weeks before screening. Exclusion Criteria: - women who are pregnant, breastfeeding or using unreliable birth control methods; - administration of another investigational drug within 4 weeks before screening, or during the study period.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Anemia", "Epoetin Alfa"], "id": "NCT00081484"}